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Abstract
Depression is a condition with various modes of treatment, including pharmacotherapy,
psychotherapy, and some combination of each. The role of psychotherapy in the treatment of
depression relative to the role of pharmacotherapy is not well understood, and guidelines for
psychotherapy in the primary care setting differ from guidelines for specialty care. There is little
evidence about the circumstances in actual practice that affect the use of psychotherapy in
conjunction with pharmacotherapy.
We retrospectively identify the most important factors associated with the use of
psychotherapy in combination with pharmacotherapy in the treatment of depression. Specifically,
we study provider choice, health plan characteristics, and patient characteristics.
We use a comprehensive medical and pharmacy claims data sample of 1,023 individuals
during 1992–1994. We select persons prescribed with an antidepressant medication and
diagnosed with a depressive disorder by a primary care physician, psychiatrist, or non-physician
mental health specialist. Controlling for depression diagnosis and severity, comorbidity, and
demographics, we examine the role of provider type and plan benefit characteristics. We study
the intensity of psychotherapy using zero-inflated count regression, the intensity of
pharmacotherapy using truncated count regression, and the likelihood of relapse of depression
using logistic regression.
Patients initially seeing a psychiatrist receive more than double the amount of
psychotherapy and slightly more pharmacotherapy than patients of other providers. An additional
prescription for antidepressant medication reduces by five percent the likelihood of relapse into
depression, but the amount of psychotherapy does not affect relapse. Patients seeing a
psychiatrist are half as likely to relapse, independent of any effect of psychotherapy. Case
management and coinsurance rates do not affect the amount of psychotherapy, but the presence
of case management has a positive effect on the amount of pharmacotherapy and on the
likelihood of relapse.
We find no discernible pattern of complementarity or substitution between
pharmacotherapy and psychotherapy across providers. Although the amount of psychotherapy
provided in conjunction with medication does not affect the rate of relapse to depression,
psychotherapy may nonetheless provide beneficial outcomes not studied here. Choice of a
psychiatrist reduces the likelihood of relapse, independent of the number of psychotherapy
sessions and antidepressant prescriptions. The effect of provider choice on relapse could be an
artifact of differences in provider follow-up practices or could represent a difference in provider
skills. Managed care strategies do not appear to reduce the intensity of depression treatment, but
case management does increase the likelihood of relapse.
Pharmacotherapy and psychotherapy appear to be neither substitutes nor complements in
the treatment of depression, suggesting that treatment is individualized. Choice of psychiatrist as
the initial provider appears to reduce the likelihood of relapse, suggesting models of coordinated
care may be beneficial. The link between psychiatrists and more psychotherapy is consistent with
the hypothesis that patients resistant to treatment may nonetheless receive high quality care.

Managed care tools such as case management and coinsurance rates do not appear to
restrict the use of either psychotherapy or pharmacotherapy. The association of case management
with an increased likelihood of relapse suggests that plan characteristics can affect outcomes.
Our study focuses on psychotherapy combined with medication and does not
psychotherapy alone in the treatment of depression, which may be a preferred mode of treatment
for some. Outcomes other than relapse, as well as costs, should also be considered. Our findings
that psychiatrists are associated with a decreased likelihood of relapse and that case management
is associated with an increased likelihood of relapse despite a correlation with greater
pharmacotherapy intensity present avenues for additional study.
Key Words: depression, psychotherapy, pharmacotherapy, relapse, count models, zero inflated
negative binomial regression

1. Introduction
The role of psychotherapy in the treatment of depression has been a subject of some
uncertainty in recent years as pharmacotherapies have proliferated. A recent study has shown
that the proportion of individuals treated with psychotherapy has declined even though the rate of
outpatient treatment for depression has increased (Olfson et al. 2002). Although psychotherapy
alone is recognized as an efficacious treatment, it is often provided in combination with
antidepressant medication in the treatment of depression. Psychotherapy in conjunction with
medication may be beneficial not only as a direct treatment of the depressive disorder and its
symptoms but also as an aid both to medication compliance (Paykel 1995) and family support of
treatment (Miller 1996). However, although combined treatment has been shown to be more
efficacious than unimodal treatment in specific contexts (Keller et al. 2000), generally the
indications for combination treatment are unclear, and guidelines for treatment in the primary
care setting differ from guidelines for psychiatric specialty care (Persons 1996). Here we
examine how pharmacotherapy and psychotherapy are paired in practice across providers in the
treatment of depression and the ultimate consequences of the mix of pharmacotherapy,
psychotherapy, and provider for relapse into depression.
The circumstances in actual practice under which psychotherapy is best combined with
antidepressant medication are not well understood. Aside from provider and patient preferences,
additional factors can affect the use of psychotherapy, such as availability and cost (Thase 1997).
Previous work has identified a need for examination of the practice of psychotherapy, including
psychotherapy with concurrent pharmacotherapy, as well as characterization of patients in terms
of diagnosis, severity, comorbidity, and demographics (Clarkin 1996).

Other work has suggested that characteristics of the health care system can affect the use
of psychotherapy in treating depression. Data from the Medical Outcomes Study showed that
depressed patients of general medical clinicians receive less counseling than patients of mental
health specialists and that health plan prepayment is associated with lower counseling rates
(Meredith et al. 1996). In addition, although the cost-containment incentives of managed care
organizations have been cited as a potential reason for reductions in the use of psychotherapy,
some observers have suggested that psychotherapy, if shown to be cost-effective, might be more
compatible with managed care than with traditional health insurance arrangements (Sharfstein
1999). Indeed, in the context of severe mental illness, psychotherapy has been associated with
reduced costs (Gabbard 1997). Thus, the relationship between the use of psychotherapy and
managed care strategies is not clear.
Recent evidence suggests that psychotherapy and pharmacotherapy are productive
complements in treating depression, meaning that they have similar therapeutic effects, ceteris
paribus (DeRubeis 1999). However, in clinical practice they need not be used in isolation (as
therapeutic substitutes in depression treatment), but rather together (as complementary
treatments). Our results shed light on the degree to which, in practice, psychotherapy and
pharmacotherapy are substitutes, complements, or appear unconnected quantitatively.
Specifically, we attempt to identify retrospectively the most important factors associated with the
use of psychotherapy in combination with medication in the treatment of depression using a
claims data sample of persons diagnosed with depression and receiving a prescription for an
antidepressant medication to study how psychotherapy is used in conjunction with
pharmacotherapy.
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Our results suggest that patients initially seeing a psychiatrist get substantially more
psychotherapy and slightly more pharmacotherapy than patients initially seeing other nonpsychiatrist providers of anti-depression care. We find no evidence that the two types of
therapies are used in conjunction or that more of one is used in place of less of the other therapy
in depression treatment. Concerning the downstream benefits of pharmacotherapy and
psychotherapy, our results indicate that pharmacotherapy lessens the likelihood of relapse into
depression, but that psychotherapy does not affect relapse; however patients seeing a psychiatrist
are less likely to relapse net of any effect of psychotherapy.

2. Methods
Our objective is to disentangle the relative quantitative importance of factors influencing
the intensity of psychotherapy in individuals treated for depression with antidepressant
medication. We use a retrospective claims database of persons diagnosed with depression and
treated with antidepressant medication with or without psychotherapy. Using multivariate
statistical models that are appropriate for dependent variables that take on non-negative integer
values and that may also be truncated, we assess whether the factors influencing psychotherapy
are jointly determined with the intensity of medication use. Finally, we examine the relationship
among psychotherapy, pharmacotherapy, and a downstream outcome of interest in the treatment
of depression, the likelihood of relapse.
2.1 Data and Variable Definitions
Our data, which come from the MarketScan database, contain comprehensive medical
and pharmacy claims data for about 700,000 employed persons and their families who worked in
20 different self-insured Fortune 500 companies (The MEDSTAT Group, Ann Arbor, MI).
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Health insurance benefits offered by employers include indemnity and managed care plans that
were dominated by preferred provider organizations. The particular MarketScan information
we use centers on claims data for continuously enrolled individuals and their plan benefit
information from 1992 through 1994.
Available claims information covers eight quarters post-depression diagnosis and two
quarters pre-depression diagnosis. We select antidepressant recipients diagnosed with a
depressive disorder by a primary care physician, a psychiatrist, or a non-physician mental health
specialist. To identify new treatment episodes we exclude persons with any claims for
psychotherapy or antidepressants in the six-month period prior to the diagnosis of depression.
We include only people with information about plan benefit characteristics. Our final sample size
used in estimation is 1,023.
Table 1 lists the variables of interest in the study sample. In addition to demographic
information about the patient’s age, sex, and the number of comorbid conditions, we examine
effects of the specific depression diagnosis and the type of provider associated with the initial
depression diagnosis. We also attempt to account for propensity to use health care and overall
health by including non-psychiatric costs in the quarter prior to the diagnosis. We account for the
intervening influence of the number of anxiolytic prescriptions filled after the depression
diagnosis, which could correspond to the level of psychiatric distress, be an indicator of
prescription-filling behavior, or measure inappropriate treatment of depressive symptoms. To
examine the effect of characteristics of the health plan and to purify the estimated effects of
provider on outcomes of interest in a multivariate setting, we include as control variables the
outpatient psychiatric coinsurance rate and whether the health plan employed case management
practices. We identify relapse or recurrence of depression when the claims data include any of
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the following: a new episode of drug therapy follows a gap of six or more months in medication
claims, a suicide attempt, a psychiatric hospitalization; a mental health related emergency
department visit, or electroconvulsive therapy.1
2.2 Data Analytic Procedures
To study the use of psychotherapy and pharmacotherapy in some quantitative detail, we
expand on simple univariate comparisons in by employing multivariate models of the number of
psychotherapy visits and antidepressant prescriptions that account for the substantial number of
nonusers of psychotherapy and the fact that all patients had at least one antidepressant
prescription. Our list of categorical explanatory variables includes depression diagnosis
indicators, with Depression Not Otherwise Specified as the reference category, and diagnosing
provider indicators, with Primary Care Physicians as the reference category. The amount of
psychotherapy is determined by the number of psychotherapy visits after the depression
diagnosis, and the amount of pharmacotherapy by the number of antidepressant prescriptions.
Because the dependent variables we study are each a non-negative integer we use count data
models rather than standard regression models in which the dependent variable is assumed to be
a continuous variable.2
The Poisson regression model is the most basic count model, but it invokes the restriction
of equality between mean and variance, termed equi-dispersion. Because preliminary results
show that the conditional mean and variance are unequal for each of the two therapies we study
in our sample, we employ the more general Negative Binomial multivariate model, which is a
generalization of the Poisson model that allows for overdispersion (the conditional variance
exceeds the conditional mean) and has been productively applied to models of health care
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utilization (Cameron and Trivedi 1998; Freund, Kniesner, and LoSasso 1999; Jones 2000;
Winkelmann 2000).
Expressed algebraically, the conditional mean value of a therapy level in a sample where
i indexes a case of depression is
E ( yi | xi ) = λi = exp(b′xi ) ,

(1)

where b is the vector of parameters to estimate that determine the marginal effect of an
independent variable, x, on the discrete value of therapy incidence, y. Additionally, the negative
binomial count model includes an overdispersion parameter, δ, that parameterizes the prevalent
form of heteroskedasticity where the conditional variance exceeds the conditional mean, λ,
which is prevalent in count data such that
var( yi | xi ) = λi (1 + λiδ ) .

(2)

Equation (2) illustrates how the negative binomial specification nests inside it the Poisson model,
and that if δˆ = 0 then the Poisson count model appears.
An additional complexity common in models of counts is a large number of zero values.
In our case about 47 percent of the sample had no claim for psychotherapy, and we attempt to
account for the high proportion of patients not receiving psychotherapy in the statistical model.
Although the Negative Binomial model accommodates a large number of zeros, we also estimate
variations of the Negative Binomial model that further adjust for so-called excess zeros in the
sample termed the zero-inflated Negative Binomial model. The ZINB model adds what is termed
a splitting parameter, q, that is the proportion of zero use that will occur no matter what the
values of the independent variables might be (some people will never submit to psychotherapy).
E ( yi | xi ) = λi (1 − qi ( x))

(3)

and
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var( yi | xi ) = λi (1 − qi )[1 + λi (qi + δ )] .

(4)

Using the same list of explanatory variables we also examine models of the intensity of
pharmacotherapy for depression where the dependent variable is the number of antidepressant
medication prescriptions filled. To expand upon a simple comparison of means we again use a
multivariate count regression model. However, because our sample of depressed persons is
constructed by locating patients with at least one antidepressant prescription, we must employ a
model that accounts for truncation at zero.3 We therefore use a truncated negative binomial
model to examine the marginal effect of provider type on anti-depressant medication use.
Along with the count regressions for psychotherapy, our regression for pharmacotherapy
reveals whether intensity of pharmacotherapy seems to complement, substitute for, or is largely
independent of the amount of psychotherapy. If psychotherapy complements pharmacotherapy,
then the number of psychotherapy visits should increase with the number of antidepressant
prescriptions. If they are substitutes, then the number of psychotherapy visits should decline as
the number of prescriptions increases. If neither a positive nor a negative relationship occurs
between the two therapies, then we consider decisions to use psychotherapy and
pharmacotherapy largely independent.
Lastly we examine the relative importance of the components of anti-depression
treatment on treatment success measured by the likelihood of a relapse. For ease of interpretation
we use the familiar binary (y = 0, 1) logit specification with
Prob(Relapse) = Prob(y = 1) = e β ′x /(1 + e β ′x ) ,

(5)

where we are concerned with the estimates of β to use in constructing case-mix adjusted effects
of the regressors related to the specialty of treatment provider and amounts of pharmacotherapy
versus psychotherapy. In our data relapse means that the person subsequently experienced a new
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episode of anti-depressant therapy, a suicide attempt, psychiatric hospitalization, a mental health
related emergency department visit, or electroconvulsive therapy, a measure previously shown
responsive to changes in the quality of care (Melfi et al. 1998, Sood et al. 2000).
Before discussing our results it is important to note that the regression coefficients, b in
Equation Psychotherapy in Antidepressant Patients n (1) and β in Equation (5) are not the objects
of interest, because they are not themselves the estimated effects of a change in an independent
variable. All of the models we estimate are non-linear index transformations of the regressors
with general form y = G ( f ( x)) so that marginal effects (ME) of interest must be evaluated at a
particular set of values for x, which we generally set equal to x . For a continuous regressor ME

= Ĝ′fˆ ′ , so that for the negative binomial models of pharmacotherapy and psychotherapy ME
= λˆ ( x )bˆ and for the relapse logit the marginal effect is ME = Pˆ ( x )(1 − Pˆ ( x ) βˆ , where P = Prob(y

= 1). For a discrete regressor, say provider type, ME =
yˆ ( x = 1) − yˆ ( x = 0) = Gˆ ( fˆ ( x = 1)) − Gˆ ( fˆ ( x = 0)) ≅ Pˆ ( x )(1 − Pˆ ( x ) βˆ . In the empirical results we
focus the discussion on the estimated marginal effects of provider type on the numbers of
psychotherapy visits and anti-depressant prescriptions and on the marginal effects of the intensity
of pharmacotherapy, psychotherapy, and provider type on treatment success measured by the
probability of a relapse.

3. Results
Table 1 presents the descriptive statistics for the entire sample and is stratified by the type
of provider making the initial diagnosis of depression. As in our prior research (Kniesner,
Powers, and Croghan 2002), the specialty of the first provider is significantly associated with the
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mix of treatment patients subsequently receive. Patients diagnosed by psychiatrists average about
11 claims for psychotherapy, while patients of non-physician mental health specialists average
about Psychotherapy in Antidepressant Patients.
Five claims, and patients diagnosed by primary care physicians average three to four
psychotherapy claims. Inter-provider differences in case-mix, which could reflect diagnostic
patterns or real differences in the types of patients who seek care from specific providers, are
such that psychiatrists are the main provider of treatment for cases of single episode and
recurrent major depression while non-physician mental health specialists are the main provider
of treatment for cases of dysthymia and reactive depression. Psychiatrist patients also receive
more prescriptions for anxiolytics and are less likely to relapse than those seeing other providers.
Overall, about three fourths of the sample received at least four prescriptions in the first six
months of treatment, and there were no differences among providers. Because univariate
comparisons do not reveal fully the degree of differences in case-mix among various providers,
we proceed to control for case-mix details in order to identify better the role of provider type in
the use of psychotherapy, pharmacotherapy and treatment success.
3.1 Psychotherapy Visits

Table 2 presents the zero-inflated negative binomial (ZINB) count model of the number
of psychotherapy visits. We include both model coefficients and marginal effects computed at
the means of the independent variables. Both the estimated overdispersion parameter ( δˆ ) and the
estimated zero-inflation parameter (which is a function of qˆi ) are significant statistically, which
means that the data reject both the simpler Poisson specification and the basic negative binomial
specification in favor of the ZINB count model form.4 Concerning the variables controlling for
case-mix across providers, a diagnosis of recurrent major depressive disorder is significantly and
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positively related to the number of psychotherapy visits, resulting in approximately four to five
additional psychotherapy visits, such that the number of visits for a major depressive disorder is
about twice the mean. The effects of all other types of depression are small and insignificant
statistically as are the influences of age and gender on psychotherapy.
Neither the psychiatric coinsurance rate nor the presence of case management in the
health insurance plan are statistically significant predictors of the amount of psychotherapy.5
Using the mean amount of psychotherapy as a comparison point, ceteris paribus the existence of
case management lowers the amount of psychotherapy by about 9 percent and doubling the
coinsurance rate on mental health care reduces psychotherapy by about 7 percent, but insurance
plan characteristics appear to be statistically weak determinants of the number of psychotherapy
visits.
Because provider type appears related to the subsequent mix of treatments, a focal point
of our research effort is whether there is a statistically significant differential effect of provider,
ceteris paribus, on the use of psychotherapy. If the amount of psychotherapy is a substitute for
pharmacotherapy, then it follows that providers who use more psychotherapy should use less
pharmacotherapy. Adjusting for case-mix, diagnosis by a psychiatrist is associated with
approximately six more psychotherapy visits than if the diagnosis is by a primary care
physician.6 The result is quite different for diagnosis by non-physician mental health specialists.
In contrast to the results for psychiatrists, there is a quantitatively small but insignificant increase
in the use of psychotherapy subsequent to an initial diagnosis by a non-physician mental health
specialist. After adjusting for case-mix, diagnosis by a mental health specialist does not result in
any additional psychotherapy visits than does diagnosis by a primary care physician. Finally, we
note that the case-mix adjusted differential in the amount of psychotherapy in Table 2 between
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psychiatrists and other providers is about the same as the unadjusted difference in Table 1;
patients whose initial providers were psychiatrists got about twice the psychotherapy as patients
whose initial providers of anti-depression therapy were general medical practitioners or
non-physician mental health specialists.
3.2 Anti-depressant Medication

The results for the truncated count model of anti-depressant prescriptions are presented in
Table 3. The most striking result is that the presence of case management in the health plan is
significantly associated with the number of antidepressant prescriptions, increasing the number
of prescriptions by more than three. Using the mean as a point of reference, case management
increases the intensity of pharmacotherapy by about 30 percent. No other covariates had a large
statistically significant estimated marginal effect. The most important result to emerge from our
truncated negative binomial count model of anti-depression pharmacotherapy is that the
case-mix adjusted results for inter-provider differences mimic the unadjusted results of Table 1.
We find no differences across the initial provider in the amounts of anti-depressant prescriptions
that patients fill.7
3.3 Relapse

One way to assess the success or failure of anti-depression treatment is by examining
whether a person receives any therapy at all or discontinues therapy early, failing to complete
and adequate amount of therapy according to recommended guidelines (Dobrez et al. 2000;
Kniesner, Powers, and Croghan 2002). Another way is to examine the downstream consequences
of therapy by examining whether a patient suffers a relapse of depression. In our data about 22
percent of patients suffer a relapse. Table 4 presents logit coefficient estimates for how intensity
of treatment and provider type influence the probability of a relapse, ceteris paribus.
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The most notable results concerning treatment success as indicated by a reduced
likelihood of a relapse relate to a subtle aspect of having a psychiatric provider. In Table 4 we
capture treatment in three dimensions: the amount of psychotherapy, the amount of
pharmacotherapy, and the type of treatment provider. Remember that the count regression results
in earlier tables had patients of psychiatrists receiving significantly more psychotherapy. Thus,
one way a psychiatrist could affect the success of treatment for depression was through greater
amounts of psychotherapy. The results in Table 4 reveal that the number of psychotherapy visits
does not affect the likelihood of a relapse.
Although the amount of psychotherapy does not affect relapse, the amount of
pharmacotherapy does affect relapse in our data. Using the mean as a reference point, an extra
anti-depressant prescription lowers the probability of relapse by approximately 4 to 5 percent
(−0.01/0.22). Our results in Table 3 indicated no differences in the amount of pharmacotherapy
patients receive across providers; however, there is no direct effect of having a psychiatric
provider operating through differential amounts of anti-depression medication.
What we find is more subtle. Holding psychotherapy visits and anti-depressant
prescriptions constant, having a psychiatric initial provider lowers the probability of relapse by
almost 50 percent using the mean likelihood of relapse as a reference point
n / P = −0.109 / 0.223 = 0.49 ). In our data there appears to be a benefit to having a psychiatric
( ME

provider, in terms of reducing the chance of relapsing into depression, that is over and above the
measured amounts of psychotherapy and pharmacotherapy psychiatrists provide relative to other
providers.
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4. Discussion
Our research objectives have centered on understanding any connections among the
amounts of psychotherapy received by depressed patients who also receive an antidepressant
with an eye for several questions of medical interest. Do there appear to be significantly different
amounts of psychotherapy across providers, how large are the inter-provider differences in
psychotherapy, and are psychotherapy and pharmacotherapy used as substitutes or complements
in the treatment of depression? Finally, are there quantitatively important inter-provider
differences in anti-depression treatment success as measured by relapse likelihood and how is
any difference related to inter-provider differences in the amounts of pharmacotherapy versus
psychotherapy?
We find that after adjusting for case-mix psychiatrists’ patients receive almost twice the
number of psychotherapy visits but fill no more prescriptions for anti-depressant medication than
the patients of general medical providers or non-physician mental health specialists. In the sense
that psychiatrists’ patients get more psychotherapy than other providers’ patients but no more or
less pharmacotherapy, there is no pattern of complementarity or substitution of one type of
therapy for the other across providers. It appears that decisions regarding use of psychotherapy
and pharmacotherapy are largely independent.
Although the research presented here generally agrees with prior research there are
patterns of treatment we observe that are somewhat surprising. For example, although the first
treatment for depression appears to depend largely on the specialty of the provider at the point of
entry (Powers et al. 2000), the number of visits and the number of prescriptions appears
independent of who first diagnosed a patient’s depression. The only exception to the
diagnoser-treatment pattern is the finding that psychiatrists use more psychotherapy than other
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providers; whether a patient first entered care through a general medical doctor or a nonphysician specialist makes no difference in the relative amount of psychotherapy and
pharmacotherapy received.
Our research has several implications for research, clinical practice, and mental health
policy. The notion that receiving treatment from psychiatrists may be associated with reductions
in the incidence of relapse is provocative, but we must acknowledge a possible confound
imposed by how relapse is identified here. Specifically, relapse here means that a new “clean”
period with no evidence of pharmaco- or psychotherapy occurs between two episodes of
medication treatment. However, we could fail to observe such a gap in treatment because of the
increase in the number of psychotherapy visits associated with psychiatrists. Suppose, for
example, that psychiatrists are more likely to see patients intermittently in follow up for a prior
episode. If the frequency of follow up visits is every three months or more, then we do not
observe a “clean” period and thus have no opportunity to observe a relapse even if one occurs
clinically. Thus, our results regarding psychiatrists should be interpreted with caution but provide
an opportunity to investigate further the relationship between provider type and relapse.
As is true for other studies that rely on MarketScanTM data, we report relative high levels
of quality of pharmacotherapy. Nearly three in four patients in our study received care consistent
with a measure used in prior research to monitor adherence to clinical practice guidelines. The
relatively high baseline in mind, it appears that psychiatrists are more likely than other providers
to offer additional psychotherapy to their patients. Our findings of a link between initial provider
and psychotherapy are consistent with the hypothesis that the additional psychotherapy may be
used for patients whose symptoms are resistant to treatment but who nonetheless may receive
high quality treatment, which is another line of research to pursue.
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Case management is utilized by about a third of the plans studied here and is associated
with more prescriptions. Because the case management identified in MarketScanTM represents a
form of utilization review designed to limit care to those most in need, we hypothesize that plans
which make use of such a cost-containment tool may also utilize quality improvement strategies
that will result in better care. Because we cannot explicitly control for depression severity in our
study, our finding of a positive correlation between case management and the probability of
relapse might suggest that plans target case management toward patients who are more severely
depressed and, therefore, more likely to relapse. Our finding of a positive link between case
management and pharmacotherapy intensity represents both an opportunity for research and an
example for clinical practice.
Finally, we point to the finding that pharmacotherapy and psychotherapy appears to be
used independently and not as substitutes or complements. Because the two treatments have
similar efficacy rates, economists have tended to view them as perfect substitutes. We suggest,
however, that physicians appear to apply the two therapies on an individual basis, perhaps
attempting to individualize treatment based on need and patient preferences, a worthy if difficult
goal.
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1.

For another example of a similar claims-based method of identifying relapse see Sood, et
al (2000).

2.

OLS is clearly a misspecified functional form as the dependent variable is both bounded
and bunched at zero. Alternatives to count models include ordered probit, Tobit, or an
exponential functional form estimated with non-linear least squares. For empirical
examples see Delgado and Kniesner (1997) and for discussion of the relative strengths
and weaknesses of alternative models see Cameron and Trivedi (1998).

3.

Adjusting for truncation involves rescaling the likelihood that the pharmacotherapy
dependent variable takes on any particular value by the inverse of the probability of y > 0
(Greene 1998).

4.

The zero generating process was modeled as a logistic function of all x’s. Changing the
list of regressors or functional form of the zero generating process proved uninformative.
The estimated zero inflation statistic in Table 2 is the Vuong (1989) statistic that is used
to check the non-nested hypothesis whether the zero-inflated negative binomial model
detects excess zeros after controlling for overdispersion (Greene 2000). When a ZINB
model is supported by the data the absolute value of the computed Vuong statistic is at
least 2.0. As a point of reference the estimated marginal effect of psychiatrist is about 15
percent smaller in a model where possible zero inflation is ignored incorrectly in our
data.

5.

We note that lack of a coinsurance rate effect is driven by the fact that the rate varies little
across the patients of primary care physicians and other mental health specialists. A
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separate count regression for only the patients of psychiatrists shows a significantly
negative coinsurance rate effect on psychotherapy visits such that a doubling of the
coinsurance rate leads to 25 percent fewer visits. The possibility of heterogeneity in the
effect of health care plan characteristics across providers remains an interesting issue for
future research.
6.

As a basic robustness check we estimated the psychotherapy model in Table 2 using
Tobit regression. The results were similar in that the estimated marginal effect of having
a psychiatric provider was a statistically significant 6.2 additional visits with no
significant difference for non-physician mental health specialist.

7.

As a basic robustness check we also estimated the pharmacotherapy model in Table 3
using truncated normal regression (Greene 2000). The results were similar in that there
were also no statistically significant differences across providers in the number of antidepressant prescriptions filled.
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Table 1: Descriptive Statistics Stratified by Provider – Mean (Standard Deviation)
Non-Physician
Mental Health
Primary Care
Psychiatrist
Specialist
Physician
(n = 272)
Variable
Total
(n = 163)
(n = 588)
Psychotherapy Visits
5.727
10.882
5.098
3.517
(10.262)
(12.726)
(8.630)
(8.409)
Antidepressant Prescriptions
11.413
12.456
11.123
11.010
(9.255)
(9.815)
(9.459)
(8.903)
Anxiolytic Prescriptions
2.895
4.272
3.160
2.185
(7.658)
(9.905)
(9.953)
(5.299)
Relapse
0.223
0.154
0.233
0.252
(0.416)
(0.362)
(0.424)
(0.434)
4+ Antidepressant Prescriptions
0.765
0.739
0.785
0.772
(0.424)
(0.440)
(0.412)
(0.420)
Log Medical Costs
8.031
8.035
8.260
7.966
(1.341)
(1.545)
(1.171)
(1.277)
Age
42.642
42.188
41.865
43.068
(9.335)
(10.087)
(8.336)
(9.227)
Female
0.738
0.665
0.724
0.776
(0.440)
(0.473)
(0.448)
(0.418)
Major depression, single episode
0.179
0.313
0.135
0.129
(0.383)
(0.464)
(0.343)
(0.336)
Major depression, recurrent
0.109
0.265
0.141
0.029
(0.312)
(0.442)
(0.349)
(0.168)
Dysthymia
0.264
0.313
0.460
0.187
(0.441)
(0.464)
(0.500)
(0.390)
Reactive depression
0.077
0.066
0.239
0.037
(0.267)
(0.249)
(0.428)
(0.190)
Depression NOS
0.370
0.044
0.025
0.617
(0.483)
(0.206)
(0.155)
(0.486)
Log Pre-Diagnosis Costs
4.568
4.301
4.892
4.602
(2.622)
(2.836)
(2.686)
(2.490)
Comorbidities
6.829
6.688
7.190
6.794
(2.992)
(3.182)
(2.856)
(2.934)
Mental Health Coinsurance Rate
0.126
0.140
0.120
0.121
(0.095)
(0.121)
(.087)
(.083)
Case Management
0.362
0.379
0.288
0.374
(0.481)
(0.486)
(0.454)
(0.484)
Source: Authors’ calculations.
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Table 2: Psychotherapy Visits – Zero Inflated Negative Binomial Regression
Marginal
Coefficient Std. Error
Effect
t-ratio
P-value
Std. Error
Constant
1.671
0.281
5.951
0.000
11.745
3.294
Age
−0.013
0.005
−2.732
0.006
−0.094
0.065
Female
0.104
0.118
0.879
0.380
0.731
1.389
Major depression, single episode
0.090
0.159
0.564
0.573
0.629
1.862
Major depression, recurrent
0.657
0.210
3.135
0.002
4.620
2.458
Dysthymia
0.253
0.115
2.193
0.028
1.775
1.350
Reactive depression
0.125
0.242
0.519
0.604
0.881
2.834
Log Pre-Diagnosis Costs
0.007
0.018
0.400
0.689
0.052
0.217
Anxiolytic Prescriptions
0.030
0.008
3.678
0.000
0.214
0.102
Comorbidities
0.010
0.018
0.562
0.574
0.072
0.217
Psychiatrist
0.950
0.201
4.737
0.000
6.676
2.353
Non-MD Mental Health Specialist
0.225
0.154
1.459
0.145
1.580
1.808
Plan Coinsurance Rate
0.621
0.475
7.282
−0.444
−0.715
−3.122
Case Management
0.099
0.482
1.157
−0.069
−0.702
−0.487
Overdispersion Parameter
2.316
0.389
5.950
0.000
Zero Inflation Parameter
0.329
0.006
−0.895
−2.723
Source: Authors’ calculations.
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t-ratio
P-value
3.565
0.000
−1.456
0.146
0.527
0.599
0.338
0.736
1.880
0.060
1.314
0.189
0.311
0.756
0.237
0.812
2.102
0.036
0.333
0.739
2.838
0.005
0.874
0.382
0.668
−0.429
0.674
−0.421

Table 3: Antidepressant Prescriptions – Truncated Negative Binomial
Marginal
Coefficient Std. Error
Effect
t-ratio
P-value
Std. Error
Constant
1.716
0.196
8.773
0.000
18.194
5.993
Age
0.004
0.004
0.951
0.341
0.043
0.049
Female
0.084
0.845
0.932
−0.016
−0.196
−0.175
Major depression, single episode
0.121
0.109
1.114
0.265
1.285
1.265
Major depression, recurrent
0.137
0.152
0.901
0.368
1.452
1.746
Dysthymia
0.100
0.174
1.216
−0.136
−1.359
−1.438
Reactive depression
0.048
0.159
0.300
0.764
0.505
1.761
Log Pre-Diagnosis Costs
0.003
0.014
0.202
0.840
0.031
0.160
Anxiolytic Prescriptions
0.035
0.014
2.552
0.011
0.369
0.194
Comorbidities
0.015
0.006
2.474
0.013
0.158
0.089
Psychiatrist
0.038
0.097
0.391
0.696
0.401
1.081
Non-MD Mental Health Specialist
0.049
0.108
0.456
0.648
0.521
1.207
Plan Coinsurance Rate
0.193
0.378
0.510
0.610
2.047
4.239
Case Management
0.326
0.079
4.136
0.000
3.452
1.446
Overdispersion parameter
0.836
0.062
13.395
0.000
Source: Authors’ calculations.
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t-ratio
P-value
3.036
0.002
0.877
0.381
0.851
−0.187
1.016
0.310
0.832
0.406
0.237
−1.182
0.286
0.775
0.193
0.847
1.906
0.057
1.780
0.075
0.371
0.711
0.432
0.666
0.483
0.629
2.387
0.017

Table 4: Relapse – Logit Regression
Coefficient
Constant
Age
Female
Major depression, single episode
Major depression, recurrent
Dysthymia
Reactive depression
Log Pre-Diagnosis Costs
Anxiolytic Prescriptions
Comorbidities
Psychiatrist
Non-MD Mental Health Specialist
Plan Coinsurance Rate
Case Management
Antidepressant Prescriptions
Psychotherapy Visits
Source: Authors’ calculations.

−0.322
−0.013
−0.338
−0.103
−0.133
0.076
0.176
−0.015
0.036
0.077
−0.682
−0.216
−0.986
0.565
−0.063
0.004

Std. Error
0.449
0.009
0.189
0.258
0.338
0.221
0.335
0.032
0.011
0.029
0.241
0.253
0.378
0.165
0.011
0.009
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t-ratio
P-value
0.473
−0.717
−1.443
0.149
0.074
−1.790
0.690
−0.399
0.695
−0.392
0.343
0.732
0.524
0.600
0.641
−0.466
3.261
0.001
2.617
0.009
0.005
−2.829
0.393
−0.853
0.510
0.610
3.420
0.001
0.000
−5.945
0.510
0.610

Marginal
Effect
Std. Error
0.052
0.072
−0.002
0.001
0.030
−0.054
0.041
−0.017
0.054
−0.021
0.012
0.035
0.028
0.054
0.005
−0.002
0.006
0.002
0.012
0.005
0.038
−0.109
0.040
−0.035
2.047
4.239
0.091
0.026
0.002
−0.010
0.001
0.001

t-ratio
P-value
0.472
−0.719
−1.445
0.149
0.073
−1.794
0.690
−0.399
0.695
−0.392
0.343
0.732
0.524
0.600
0.641
−0.466
3.267
0.001
2.625
0.009
0.004
−2.851
0.393
−0.854
0.483
0.629
3.450
0.001
0.000
−6.229
0.510
0.610
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